B Vitamins Reduce Homocysteine, But Not Disease in Diabetic Patients
G. Douglas Andersen, DC, DACBSP, CCN
Whenever the topic of kidney disease arises in my practice, the first thought that crosses my mind is diabetes, since almost 40 percent will eventually have kidney problems.1 There is evidence of a correlation between homocysteine levels in diabetic patients and diseases of the kidneys, heart and eyes.2 To lower homocysteine, we have a powerful, proven way to do it with three members of the B vitamin family.3 Many health care professionals have reasonably concluded that lowering homocysteine lowers the risk, degree or progression of secondary problems often seen in patients with diabetes.
Homocysteine: What Is Normal?
Normal plasma homocysteine values vary widely between labs and can range from as low as 2.2 to as high as 17 micromoles per liter (abbreviated as mcmol/L or umol/L). Homocysteine increases with age and runs ~1.5 umol/L higher in males than females. There is a debate on what is optimal, and this too is affected by gender and age. In general, "optimal homocysteine" ranges run from less than 10 to under 6 umol/L.
The DIVINe Study
The Diabetic Intervention with Vitamins to Improve Nephropathy (DIVINe) study followed a screened group of diabetic patients with kidney disease for three years. Those who met the criteria had diabetic nephropathy, but their condition was not considered advanced.4 The 238 subjects who qualified were divided into two groups. One took 2,500 mcg of folic acid, 1,000 mcg of vitamin B12, and 25 mg of vitamin B6 a day. The second group took a look-alike placebo. Eighty-three percent of the patients were white male, 81 percent had type 2 (as opposed to type 1) diabetes, and their mean age was 60. Plasma homocysteine levels at baseline were 16.4 umol/L and 14.7 umol/L in the placebo and B-vitamin groups, respectively.
Results
In approximately three years of follow-up, the B-vitamin group had mean homocysteine levels decline from 14.7 umol/L to 12.5 umol/L, while those assigned to placebo had their averages increase from 16.4 umol/L to 19 umol/L. However, the B-vitamin group also had an accelerated rate of GFR decrease, more strokes and more heart attacks. [See table]
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant, 2008;23(4):1216-23.
It’s a new year and many chiropractors are evaluating what will enhance their respective practices, particularly as it relates to their bottom line. One of the most common questions I get is: “Do I need to be credentialed to bill insurance, and what are the best plans to join?” It’s a loaded question – but one every DC ponders. Whether you're already in-network or pondering whether to join, here's what you need to know.
A 36-year-old female presented on Nov. 18, 2025, with lumbar pain and left lower extremity radiculopathy. Following a comprehensive history, physical examination, and radiographic evaluation to assess anatomical and biomechanical factors, an immediate lumbar MRI was ordered due to the patient’s radiculopathic symptoms and clinical findings.
Mark Studin, DC, FPSC, FASBE(C), DAAPM;
Timothy Clare, DC, FPSC(C)
What happens when best practices for patient care fall outside what guidelines endorse or insurance will cover? More importantly, how can clinicians ethically and effectively integrate non-reimbursed services that improve function, reduce disability and support long-term outcomes? These are not just clinical questions; they are economic and policy challenges that directly affect practice viability and patient access.
